Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Beam Therapeutics Inc.NASDAQ: BEAM

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt turns positive

Q2 FY2026 net debt was $27.53M, compared with -$127.33M a year earlier.

Context

  • Net debt amounted to 2.0% of total assets at the end of Q2 FY2026, down 7.2 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +121.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.53M+173.5% QoQ
Last fiscal yearDec 2025
-$1.06M+99.1% YoY
Year agoJun 2025
-$127.33M+121.6% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+121.6%——
1 year+99.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(1.06M) USD
Year-over-year change
+99.1%

Net Debt vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's Jun 2026 net debt of $27.53M is the 5th highest of the 9 companies compared; the peer median is $26.05M.
  • Its year-over-year change of +121.6% is the 4th highest of 9, against a peer median of +41.3%.
  • Net debt amounts to 2.0% of total assets for BEAM, versus a peer median of 18.0%.
BEAM Competitors Peer median
Net Debt for BEAM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRSPCRISPR Therapeutics AGSep 2026$587.8M +416.6%+7.3%23.0%
CLLSCellectis S.A.Mar 2026$73.6M +305.2%—25.5%
ALLOAllogene Therapeutics, Inc.Mar 2026$50.74M +30.7%-7.0%12.8%
FATEFate Therapeutics, Inc.Mar 2026$37.22M -3.1%-13.4%13.1%
BEAMBeam Therapeutics Inc.Jun 2026$27.53M +121.6%—2.0%
CRBUCaribou Biosciences, Inc.Mar 2026$14.89M +566.3%—10.0%
EDITEditas Medicine, Inc.Mar 2026-$51.67M +52.0%—34.6%
NTLAIntellia Therapeutics, Inc.Mar 2026-$54.21M -610.7%—7.1%
DTILPrecision BioSciences, Inc.Mar 2026-$70.9M -49.4%—49.3%
Peer median (excluding BEAM) $26.05M+41.3%-7.0%18.0%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents559.99M232.77M435.9M281.97M294.94M
Short-term Investments405.65M845.37M753.98M568.77M950.27M
Net Receivables300M0000
Inventory00000
Other Current Assets014.76M21.17M27.41M0
Total Current Assets1.27B1.09B1.21B878.15M1.27B
Property, Plant & Equipment (Net)186.98M234.13M237.81M216.28M205.18M
Goodwill00000
Intangible Assets00000
Long-term Investments00006.68M
Tax Assets00000
Other Non-current Assets14.47M14.69M10.87M9.4M634K
Total Non-current Assets201.45M248.82M248.67M225.68M212.49M
Total Assets1.47B1.34B1.46B1.1B1.48B
Account Payables7.47M9.03M1.62M3.87M10.23M
Short-term Debt2.29M00014.36M
Tax Payables00000
Deferred Revenue86.27M135.97M68.71M108.86M6.66M
Other Current Liabilities60.83M49.68M100.69M19.74M36.34M
Total Current Liabilities213.44M223.6M205.57M182.07M96.94M
Long-term Debt3.01M000139.76M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)262.3M202.18M109.89M33.22M0
Other Non-current Liabilities34.16M13.84M3.02M7.04M(133.63M)
Total Non-current Liabilities434.28M384.65M272.82M188.21M145.88M
Total Liabilities647.72M608.24M478.39M370.28M242.82M
Common Stock684K712K816K836K1.02M
Retained Earnings(768.27M)(1.06B)(1.19B)(1.57B)(1.64B)
Accumulated OCI(50K)(2.43M)604K679K1.11M
Other Stockholders Equity00000
Minority Interest00000
Total Equity826.74M733.47M981.33M733.55M1.24B
Total Debt147.64M179.01M172.69M161.43M293.88M
Net Debt(412.35M)(53.76M)(263.21M)(120.54M)(1.06M)

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.